Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment
US11020478B2 · kind B2 · utility
0Cited by
0References
23Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 20, 2019 |
| Grant date | Jun 1, 2021 |
| Priority date | — |
| Expiry date | May 20, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for modulating angiogenesis in a cancer or tumor refractory to anti-VEGF, including identifying a cancer cell as being referactory to anti-VEGF, and then contacting the cancer cell refractory to anti-VEGF with an effective amount of an agent that modulates interaction between Gal1 or a Gal1 fragment and the natural binding partner of Gal1 or the Gal1 fragment to thereby modulate angiogenesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.